Scopus Indexed Publications

Paper Details

Dostarlimab: The miracle drug for the treatment of colorectal cancer
Pollob Ahmed Shuvo, Anika Tahsin, Md. Mominur Rahman, Talha Bin Emran,

Cancer is nothing but uncontrolled cellular growth. When this uncontrolled cellular growth takes place in colon or rectum area, it is termed as colorectal cancer or simply colon cancer [1]. The epidemiology of colorectal cancer may change drastically depending on geographical locations. It is the second and third most prevalent type of cancer in females and males respectively. Incidence and mortality rates of this type of cancer is significantly lower in females than males [2,3]. Dostarlimab (brand name JEMPERLI) is a collection of laboratory-synthesized molecules which can act as substitute for human antibodies [4]. Dostarlimab is an antibody to anti-programmed cell death receptor-1 (PD-1) which is used for the treatment of adults with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors as well as dMMR-recurrent or advanced cancer in endometrium

Journal or Conference Name
Annals of Medicine and Surgery
Publication Year